Tissue Regenix Group Management
Management criteria checks 3/4
Tissue Regenix Group's CEO is Danny Lee, appointed in Nov 2020, has a tenure of 3.83 years. total yearly compensation is $621.00K, comprised of 49.1% salary and 50.9% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth €183.18K. The average tenure of the management team and the board of directors is 3.8 years and 8.2 years respectively.
Key information
Danny Lee
Chief executive officer
US$621.0k
Total compensation
| CEO salary percentage | 49.1% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.8yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$1m |
| Mar 31 2024 | n/a | n/a | -US$1m |
| Dec 31 2023 | US$621k | US$305k | -US$2m |
| Sep 30 2023 | n/a | n/a | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$581k | US$290k | -US$3m |
| Sep 30 2022 | n/a | n/a | -US$3m |
| Jun 30 2022 | n/a | n/a | -US$4m |
| Mar 31 2022 | n/a | n/a | -US$4m |
| Dec 31 2021 | US$503k | US$290k | -US$5m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$306k | US$38k | -US$12m |
Compensation vs Market: Danny's total compensation ($USD621.00K) is about average for companies of similar size in the German market ($USD509.52K).
Compensation vs Earnings: Danny's compensation has increased whilst the company is unprofitable.
CEO
Danny Lee (63 yo)
3.8yrs
Tenure
US$621,000
Compensation
Mr. Daniel Ray Lee, also known as Danny, serves as Chief Executive Officer and Director at Tissue Regenix Group plc since November 16, 2020. He was President, US Operations at Tissue Regenix Group plc sinc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$621.00k | 0.40% $ 183.2k | |
| CFO & Executive Director | 3.7yrs | US$367.00k | 0.22% $ 100.2k | |
| Technical & Operations Director - UK | no data | no data | no data | |
| Senior Vice President | no data | no data | no data | |
| EMEA Business Director & Company Secretary | 4.8yrs | no data | 0.16% $ 73.6k |
3.8yrs
Average Tenure
Experienced Management: LSW's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$621.00k | 0.40% $ 183.2k | |
| CFO & Executive Director | 3.7yrs | US$367.00k | 0.22% $ 100.2k | |
| Independent Non-Executive Director | 3.7yrs | US$44.00k | 0.22% $ 103.7k | |
| Member of Orthopedic Clinical Advisory Board for US | 8.2yrs | no data | no data | |
| Independent Non-Executive Director | 3.7yrs | US$44.00k | 0.078% $ 35.9k | |
| Non-Executive Chairman | 8.7yrs | US$87.00k | 0.57% $ 263.3k | |
| Independent Non-Executive Director | 8.3yrs | US$37.00k | 0.023% $ 10.6k | |
| Member of Orthopedic Clinical Advisory Board for US | 8.2yrs | no data | no data | |
| Member of Orthopedic Clinical Advisory Board for US | 8.2yrs | no data | no data | |
| Member of Orthopedic Clinical Advisory Board for US | 8.2yrs | no data | no data | |
| Member of Orthopedic Clinical Advisory Board for US | 8.2yrs | no data | no data |
8.2yrs
Average Tenure
63yo
Average Age
Experienced Board: LSW's board of directors are considered experienced (8.2 years average tenure).